Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 12.67
(-0.63%)
CNY 12.67
(-0.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.69 Billion CNY | 8.43% |
| 2022 | 1.56 Billion CNY | 6.64% |
| 2021 | 1.46 Billion CNY | 86.21% |
| 2020 | 785.86 Million CNY | 18.0% |
| 2019 | 665.96 Million CNY | 13.69% |
| 2018 | 585.77 Million CNY | 14.94% |
| 2017 | 509.65 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.68 Billion CNY | 0.52% |
| 2024 Q3 | 1.75 Billion CNY | 4.09% |
| 2024 Q1 | 1.67 Billion CNY | -0.73% |
| 2023 Q4 | 1.69 Billion CNY | 18.59% |
| 2023 FY | 1.69 Billion CNY | 8.43% |
| 2023 Q3 | 1.42 Billion CNY | 4.85% |
| 2023 Q2 | 1.36 Billion CNY | -5.32% |
| 2023 Q1 | 1.43 Billion CNY | -7.9% |
| 2022 Q3 | 1.62 Billion CNY | 11.69% |
| 2022 Q2 | 1.45 Billion CNY | 0.35% |
| 2022 Q1 | 1.44 Billion CNY | -1.16% |
| 2022 FY | 1.56 Billion CNY | 6.64% |
| 2022 Q4 | 1.56 Billion CNY | -3.75% |
| 2021 Q4 | 1.46 Billion CNY | -2.77% |
| 2021 Q3 | 1.5 Billion CNY | 90.7% |
| 2021 Q2 | 789.24 Million CNY | 4.39% |
| 2021 FY | 1.46 Billion CNY | 86.21% |
| 2021 Q1 | 756.08 Million CNY | -3.79% |
| 2020 FY | 785.86 Million CNY | 18.0% |
| 2020 Q1 | - CNY | 0.0% |
| 2020 Q4 | 785.86 Million CNY | 0.0% |
| 2020 Q2 | 589.36 Million CNY | 0.0% |
| 2019 FY | 665.96 Million CNY | 13.69% |
| 2018 FY | 585.77 Million CNY | 14.94% |
| 2017 FY | 509.65 Million CNY | 0.0% |